Nableran (Meropenem)

Meropenem, the active ingredient in Nableran, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides bactericidal treatment for severe, hospital‑acquired bacterial infections in adult and pediatric patients requiring intensive therapy.

GNH USA supplies Nableran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare providers. Our distribution network ensures timely delivery, temperature‑controlled handling where required, and full regulatory documentation for each shipment.

Meropenem is a carbapenem antibiotic indicated for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves rapid bacterial clearance and supports clinical recovery. - Complicated urinary tract infections: eradicates resistant uropathogens and reduces systemic spread. - Bacterial meningitis: penetrates the cerebrospinal fluid to provide effective bactericidal activity. - Hospital‑acquired pneumonia: treats multidrug‑resistant pathogens and improves pulmonary outcomes. - Severe sepsis: offers broad‑spectrum coverage essential for life‑threatening systemic infection.

Like all antibiotics, Meropenem may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea - Headache - Injection site pain or phlebitis - Elevated liver enzymes

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, rash, angioedema) - Clostridioides difficile‑associated colitis - Seizures, especially in patients with renal impairment - Thrombocytopenia or neutropenia - Hepatotoxicity with jaundice

Clinicians should consider several precautions when prescribing Meropenem to ensure safe and effective use.

- Renal function: adjust dose in patients with impaired clearance. - Seizure risk: monitor neurologic status, especially in those with CNS disorders. - Allergies: avoid in patients with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Concomitant nephrotoxic drugs: monitor for additive kidney injury. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may reduce serum levels, risking loss of seizure control. - Probenecid: can increase meropenem concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxicity; monitor renal function. - Loop diuretics: may enhance ototoxic potential when used together. - Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters. - Oral contraceptives: theoretical reduction in efficacy; advise backup contraception.